Latest Safety News

Worley Limited reported solid financial results for FY2025, highlighted by disciplined capital management including a $269 million share buy-back and a strong focus on sustainability. The company outlined strategic priorities and anticipates moderate growth in FY2026 with a new growth strategy to be revealed next year.

Tasmea Limited reported robust FY25 financial results with a 74% jump in net profit after tax, driven by organic growth and strategic acquisitions. The company reaffirmed its FY26 guidance, supported by a $43 million institutional placement to fuel further expansion.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Experience Co Limited reported a strong FY25 with record revenue and earnings growth, driven by its Skydiving and Adventure Experiences segments. The company is advancing organic growth and acquisitions while maintaining disciplined capital management heading into FY26.

LGI Limited reported robust FY25 results with a 14% rise in EBITDA and secured six new contracts, positioning the company for a 25-30% EBITDA increase in FY26. Key project completions and expansions underpin this momentum.

LGI Limited reported robust FY25 results, expanding electricity capacity by 44% and increasing EBITDA by 14%, driven by new landfill gas contracts and battery storage projects. The company is well positioned to capitalize on Australia’s renewable energy transition and evolving carbon credit market.

White Energy Company Limited has announced a partially underwritten entitlement offer to raise approximately $3.5 million at a 10% discount, aimed at funding key mineral exploration projects across Australia.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

Acusensus Limited has raised its FY26 revenue guidance to $83-$87 million, driven by significant new contracts in the US and New Zealand and expansions in Australia. This upgrade signals strong momentum in the company’s AI-powered road safety enforcement business.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Saunders International reported a challenging FY2025 with profit declines amid operational headwinds but strengthened its Water sector presence through the Aqua Metro acquisition. The company projects a stronger FY2026 backed by a record $4 billion pipeline and improved margins.